PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.67%
Cash & equivalents declining -3.67% while Medical - Pharmaceuticals shows -9.12% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-3.67%
Cash + STI yoy growth 0.75-0.9x the Medical - Pharmaceuticals median of -4.39%. John Neff might question if the firm invests in other areas or is missing liquidity.
-99.16%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-2.48%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
41.73%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-2.13%
Near the Medical - Pharmaceuticals median of -2.13%. Charlie Munger sees typical short-term asset management among peers.
3.82%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.63%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-10.24%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-10.24%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
11.72%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-8461.58%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1034.56%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.36%
≥ 1.5x the Medical - Pharmaceuticals median of 0.55%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-33.33%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
1.44%
Below half the Medical - Pharmaceuticals median of -0.74%. Jim Chanos might see potential stagnation or distress vs. peers.
2.52%
Payables growth above 1.5x Medical - Pharmaceuticals median of 1.49%. Jim Chanos might see a warning sign of stressed supplier payments.
-5.11%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-45.14%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-78.13%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
543.56%
Below half Medical - Pharmaceuticals median of -6.14%. Joel Greenblatt sees fewer expansions than peers.
0.21%
50-75% Medical - Pharmaceuticals median of 0.30%. Mohnish Pabrai notes fewer yoy liability expansions.
-6.91%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
130.56%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-5.46%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-0.82%
1.1-1.25x Medical - Pharmaceuticals median of -0.70%. John Neff wonders if the firm is gearing up more than peers.
No Data
No Data available this quarter, please select a different quarter.
5.79%
Below half Medical - Pharmaceuticals median of -2.10%. Jim Chanos suspects poor profitability or large dividend drains.
20.69%
Above 1.5x Medical - Pharmaceuticals median 11.41%. Jim Chanos suspects a red flag if these gains are highly volatile.
100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
5.18%
Below half Medical - Pharmaceuticals median of -1.89%. Jim Chanos suspects slower net worth growth or losses vs. peers.
1.44%
Below half Medical - Pharmaceuticals median of -0.60%. Jim Chanos suspects a major slowdown or distress.
212075.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-25.72%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-954.07%
Below half of Medical - Pharmaceuticals median 6.83%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.